SBIR TOPIC 255, PHASE II: SYNTHETIC VACCINES AGAINST PROSTATE CANCER
SBIR TOPIC 255, PHASE II: SYNTHETIC VACCINES AGAINST PROSTATE CANCER
SBIR 主题 255，第二阶段：针对前列腺癌的合成疫苗
批准号：
8351886
负责人：
PETER PUSHKO
金额：
$148.31万
依托单位：
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
项目状态：
已结题
起止时间：
2011-09-29 至 2013-09-28
关键词：
Animal ModelAntibody FormationAntigensBiological AssayCD8B1 geneCancer ControlChemistryCollaborationsContractsDataDendritic CellsDevelopmentDoseEngineeringEvaluationGenesGoalsHumanImmunotherapyMalignant neoplasm of prostateMarylandMethodsMusPhasePreparationProceduresProcessProductionProstate Cancer VaccineProstate-Specific AntigenPublic HealthQuality ControlRegimenResearchRouteSafetySerumSmall Business Innovation Research GrantStructure of base of prostateSynthetic VaccinesT-LymphocyteTransgenic MiceUnited States Food and Drug AdministrationUniversitiesVaccinatedVaccinationVaccine AntigenVaccine ProductionVaccinesVariantVirus-like particleassay developmentcancer immunotherapydesignexpression vectorfollow-upimmunogenicityimprovedin vivomeetingsnovelnovel therapeuticsnovel vaccinesprotective effectprotective efficacyresearch studyscale uptherapeutic vaccinetumorvaccine candidatevaccine efficacyvector
中文摘要
翻译
该II期SBIR合同是用于PSA+转基因小鼠免疫后的TRAMP肿瘤攻击的高级疫苗疗效研究。通过新的载体VLP （vVLP_疫苗平台）在PSA+小鼠中进行传递和表达，以提高PSA变体的免疫原性。后者代表非复制的病毒样颗粒，配置封装表达载体，用于体内递送和表达工程化PSA基因。
英文摘要
This Phase II, SBIR contract is for the advanced vaccine efficacy studies, which involve TRAMP tumor challenge of vaccinated PSA+ transgenic mice. Engineered for increased immunogenicity PSA variants will be delivered and expressed in PSA+ mice using novel ¿vector VLP¿ (vVLP_ vaccine platform. The latter represent non-replicating virus-like particles configured to encapsidate expression vector for in vivo delivery and expression of engineered PSA genes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金
